Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HINT1 | P49773 | 4/20 | 0.44 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.43 |
| ▸ | ADORA2B | P29275 | 6/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1275031 | 0.88 | HINT1 (0.58) | HINT1TAAR1NT5E | |
| SCHEMBL4527412 | 0.82 | ADORA3 (0.61) | HINT1TAAR1ADORA2AADORA2BNT5E | |
| SCHEMBL4527405 | 0.82 | ADORA3 (0.61) | HINT1TAAR1ADORA2AADORA2BNT5E | |
| SCHEMBL27375734 | 0.82 | ADORA3 (0.61) | HINT1TAAR1ADORA2AADORA2BNT5E | |
| SCHEMBL9791204 | 0.82 | ADORA3 (0.61) | HINT1TAAR1ADORA2AADORA2BNT5E | |
| SCHEMBL6829145 | 0.81 | HINT1 (0.56) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL574741 | 0.80 | ADORA3 (0.65) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL5358869 | 0.80 | ADORA2A (0.52) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL5360770 | 0.79 | HINT1 (0.56) | HINT1ADORA2AADORA2BNT5EADORA3 | |
| SCHEMBL26294891 | 0.79 | HINT1 (0.56) | HINT1ADORA2AADORA2BNT5EADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024151975-A1 | DETECTING DEGRADATION OF A POLYNUCLEOTIDE BY RAMAN SPECTROSCOPY | LEDNEV IGOR (US) | 2024-07-18 | — | — | WO | disclosed |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | MODERNATX, INC. (US) | 2024-05-14 | — | — | US | disclosed |
| EP-4351623-A1 | GENE COMBINATION AS A BROAD SPECTRUM ANTIVIRAL | Icahn School of Medicine at Mount Sinai (US) | 2024-04-17 | — | — | EP | disclosed |
| US-20240100188-A1 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-03-28 | — | — | US | disclosed |
| WO-2024015729-A1 | REGULATORY SYSTEM FOR EXPRESSION OF A GENE OF INTEREST IN A TARGET CELL AND METHOD OF USE THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2024-01-18 | — | — | WO | disclosed |
| WO-2023235568-A1 | DERIVATION OF GLUCOSE-RESPONSIVE INSULIN-SECRETING CELLS AND ORGANOIDS FROM HUMAN STOMACH CELLS AND THEIR USE TO TREAT DIABETES | CORNELL UNIVERSITY (US) | 2023-12-07 | — | — | WO | disclosed |
| WO-2023192932-A2 | INDUCED LIVER SINUSOIDAL ENDOTHELIAL CELLS (iLSECs) AND METHODS FOR SUPPORTING HEPATOCYTES USING THE iLSECs | CORNELL UNIVERSITY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2023-02-16 | — | — | US | disclosed |
| US-20230008266-A1 | SYNTHETIC MODIFIED RNA AND USES THEREOF | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-01-12 | — | — | US | disclosed |
| WO-2022261206-A1 | GENE COMBINATION AS A BROAD SPECTRUM ANTIVIRAL | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2022-12-15 | — | — | WO | disclosed |
| EP-3655040-A1 | MODIFIED MRNA ENCODING A PROPIONYL-COA CARBOXYLASE AND USES THEREOF | Modernatx, Inc. (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190307857-A1 | MODIFIED mRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | MODERNATX, INC. (US) | 2019-10-10 | — | — | US | disclosed |
| WO-2019023179-A1 | MODIFIED MRNA ENCODING A GLUCOSE-6-PHOSPHATASE AND USES THEREOF | MODERNATX, INC. (US) | 2019-01-31 | — | — | WO | disclosed |
| WO-2019018765-A1 | MODIFIED MRNA ENCODING A PROPIONYL-COA CARBOXYLASE AND USES THEREOF | MODERNATX, INC. (US) | 2019-01-24 | — | — | WO | disclosed |
| EP-3423106-A1 | BIODEGRADABLE ACTIVATED POLYMERS FOR THERAPEUTIC DELIVERY | Alexion Pharmaceuticals, Inc. (US) | 2019-01-09 | — | — | EP | disclosed |
| US-20180353618-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | MODERNATX, INC. (US) | 2018-12-13 | — | — | US | disclosed |
| EP-3386533-A1 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ModernaTX, Inc. (US) | 2018-10-17 | — | — | EP | disclosed |
| WO-2017100562-A9 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ALEXION PHARMACEUTICALS, INC, (US) | 2017-08-03 | — | — | WO | disclosed |
| WO-2017100551-A1 | HETEROLOGOUS UTR SEQUENCES FOR ENHANCED mRNA EXPRESSION | ALEXION PHARMACEUTICALS, INC. (US) | 2017-06-15 | — | — | WO | disclosed |
| WO-2017100562-A1 | MODIFIED MRNA ENCODING A URIDINE DIPHOPSPHATE GLUCURONOSYL TRANSFERASE AND USES THEREOF | ALEXION PHARMACEUTICALS, INC, (US) | 2017-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230050143-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | HINT1 541/4885TAAR1 3975/4885ADORA2A 3136/4885 |
| US-20180353618-A1 | Heterologous UTR Sequences for Enhanced mRNA Expression | RNGTT, UPF1, RNMT | HINT1 541/4885TAAR1 3975/4885ADORA2A 3136/4885 |
| US-11980672-B2 | Heterologous UTR sequences for enhanced mRNA expression | RNGTT, UPF1, RNMT | HINT1 541/4885TAAR1 3975/4885ADORA2A 3136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.